Selective binding of 2-[125I]iodo-nisoxetine to norepinephrine transporters in the brain

Nuclear Medicine and Biology

Volumn 31, Issue 5, 2004, Pages 533-541

  Kung, Mei Ping ^a   Choi, Seok Rye ^a   Hou, Catherine ^a   Zhuang, Zhi Ping ^a   Foulon, Catherine ^a   Kung, Hank F ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adrenergic neuron; Autoradiography; Brain imaging; Receptor binding; Selective norepinephrine reuptake inhibitors

Indexed keywords

2 IODONISOXETINE I 125; ESCITALOPRAM; NISOXETINE; NORADRENALIN TRANSPORTER; RADIOLIGAND; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BINDING SITE; BRAIN MAPPING; CORPUS STRIATUM; DRUG BINDING; DRUG SELECTIVITY; DRUG SPECIFICITY; HYPOTHALAMUS; LIGAND BINDING; LOCUS CERULEUS; MALE; NONHUMAN; RADIOIODINATION; RAPHE NUCLEUS; RAT; STATISTICAL SIGNIFICANCE;

ANIMALS; BRAIN; FLUOXETINE; LLC-PK1 CELLS; MALE; METABOLIC CLEARANCE RATE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; ORGAN SPECIFICITY; PROTEIN BINDING; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SWINE; SYMPORTERS; TISSUE DISTRIBUTION;

EID: 3042583657     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2004.03.001     Document Type: Article

References (41)

1. Blakely R.D., Bauman A.L. Biogenic amine transporters regulation in flux. Curr Opinion Neurobiol. 10:2000;328-336
2. Tatsumi M., Groshan K., Blakely R.D., Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 340:1997;249-258
3. Frazer A. Serotonergic and noradrenergic reuptake inhibitors prediction of clinical effects from in vitro potencies. J Clin Psychiatry. 62:2001;16-23
4. Gould G.G., Pardon M.-C., Morilak D.A., Frazer A. Regulatory effects of reboxetine treatment alone, or following paroxetine treatment, on brain noradrenergic and serotonergic systems. Neuropsychopharmacology. 28:2003;1633-1641
5. Klimek V., Stockmeier C., Overholser J., Meltzer H.Y., Kalka S., Dilley G., Ordway G.A. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci. 17:1997;8451-8458
6. Zhu M.-Y., Ordway G.A. Down-regulation of norepinephrine transporters on PC12 cells by transporter inhibitors. J Neurochem. 68:1997;134-141
7. Burrows G.D., Maguire K.P., Norman T.R. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine a review. J Clin Psych. 14:1998;4-7
8. Gorman J.M., Sullivan G. Noradrenergic approaches to antidepressant therapy. J Clin Psychiatry. 1:2000;13-16
9. Owens M.J., Nemeroff C.B. Role of serotonin in the pathophysiology of depression focus on the serotonin transporter. Clin Chem. 40:1994;288-295
10. Wong E.H., Sonders M.S., Amara S.G., Tinholt P.M., Piercey M.F., Hoffmann W.P., Hyslop D.K., Franklin S., Porsolt R.D., Bonsignori A., Carfagna N., McArthur R.A. Reboxetine a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry. 47:2000;818-829
11. Bel N., Artigas F. In vivo effects of the simultaneous blockade of serotonin and norepinephrine transporters on serotonergic function. Microdialysis studies. J Pharmacol Exp Ther. 278:1996;1064-1072
12. Bymaster F.P., Katner J.S., Nelson D.L., Hemrick-Luecke S.K., Threlkeld P.G., Heiligenstein G.H., Morin S.M., Gehlert D.R., Perry K.W. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat a potential mechanism for efficacy in Attention Deficit/Hyperactivity Disorder. Neuropsychopharmacology. 27:2002;699-711
13. Fava M., McGrath P.J., Sheu W.-P. Switching to reboxetine An efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine. J Clin Psychopharmacol. 23:2003;365-369
14. Szabo S.T., Blier P. Effects of the selective norepinephrine reuptake inhibitor reboxetine on norepinephrine and serotonin transmission in the rat hippocampus. Neuropsychopharmacology. 25:2001;845-857
15. Spencer T., Heiligenstein J.H., Biederman J., Faries D.E., Kratochvil C.J., Conners C.K., Potter W.Z. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/ hyperactivity disorder. J Clin Psychiatry. 63:2002;1140-1147
16. Van Dort M.E., Kim J.H., Tluczek L., Wieland D.M. Synthesis of 11C-labeled desipramine and its metabolite 2-hydroxydesipramine potential radiotracers for PET studies of the norepinephrine transporter. Nucl Med Biol. 24:1997;707-711
17. 11C]-nisoxetine, a norepinephrine uptake inhibitor. Nucl Med Biol. 16:1989;771-774
18. Wilson A.A., Johnson D.P., Mozley D., Hussey D., Ginovart N., Nobrega J., Garcia A., Meyer J., Houle S. Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter. Nucl Med Biol. 30:2003;85-92
19. Schou M., Halldin C., Sovago J., Pike V.W., Gulyas B., Mozley P.D., Johnson D.P., Hall H., Innis R.B., Farde L. Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S, S)-[(11)C]MeNER. Nucl Med Biol. 30:2003;707-714
20. Ding Y.S., Lin K.S., Garza V., Carter P., Alexoff D., Logan J., Shea C., Xu Y., King P. Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs. Synapse. 50:2003;345-352
21. Lin KS, Ding Y-S. Synthesis and evaluation of a new norepinephrine transporter PET ligand in nonhuman primates. J Label Compd Radiopharm 2003;46(suppl 1):S58
22. Chumpradit S., Kung M.-P., Panyachotipun C., Prapansiri V., Foulon C., Brooks B.P., Szabo S.A., Tejani-Butt S., Frazer A., Kung H.F. Iodinated tomoxetine derivatives as selective ligands for serotonin and norepinephrine uptake sites. J Med Chem. 35:1992;4492-4497
23. Gehlert D.R., Schober D.A., Hemrick-Luecke S.K., Krushinski J., Howbert J., Robertson D.W., Fuller R.W., Wong D.T. Novel halogenated analogs of tomoxetine that are potent and selective inhibitors of norepinephrine uptake in brain. Neurochem Int. 26:1995;47-52
24. Kung M.-P., Chumpradit S., Billings J.J., Kung H.F. 4-Iodotomoxetine a novel ligand for serotonin uptake sites. Life Sci. 51:1992;95-106
25. Kung M.P., Hou C., Zhuang Z.-P., Zhang B., Skovronsky D.M., Gur T., Lee V.M.-Y., Trojanowski J.Q., Kung H.F. IMPY An improved thioflavin-T derivative for in vivo labeling of b-amyloid plaques. Brain Res. 956:2002;202-210
26. Gu H., Wall S.C., Rudnick G. Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J Biol Chem. 269:1994;7124-7130
27. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with Folin phenol reagent. J Biol Chem. 193:1951;265-275
28. Munson P.J., Rodbard D. LIGAND a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 107:1980;220-239
29. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, New York, NY
30. 125I]ADAM to serotonin transporters in rat brain. Synapse. 38:2000;403-412
31. Kung M.-P., Essman W.D., Frederick D., Meegalla S., Goodman M., Mu M., Lucki I., Kung H.F. IPT a novel iodinated ligand for the CNS dopamine transporter. Synapse. 20:1995;316-324
32. 3H]-Nisoxetine a radioligand for quantification of norepinephrine uptake sites by autoradiography or by homogenate binding. J Pharmacol Exp Ther. 260:1992;427-436
33. Gehlert D.R., Schober D.A., Gackenheimer S.L. Comparison of (R)-[3H]tomoxetine and (R/S)-[3H]nisoxetine binding in rat brain. J Neurochem. 64:1995;2792-2800
34. Cortes R., Soriano E., Pazos A., Probst A., Palacios J.M. Autoradiography of antidepressant binding sites in the human brain localization using [3H] paroxetine. Nueroscience. 27:1988;473-496
35. 125I]5- Iodo-6-nitroquipazine a potent and selective ligand for the 5-hydroxytryptamine uptake complex II in vivo studies in rats. Brain Res. 619:1993;236-246
36. 3H-paroxetine-labeled serotonin uptake sites in rat brain. Synapse. 1:1987;488-496
37. Kovachich G.B., Aronson C.E., Brunswick D.J., Frazer A. Quantitative autoradiography of serotonin uptake sites in rat brain using [3H]cyanoimipramine. Brain Res. 454:1988;78-88
38. Kiyono Y., Kanegawa N., Kawashima H., Fujiwara H., Iida Y., Nishimura H., Saji H. A new norepinephrine transporter imaging agent for cardiac sympathetic nervous function imaging radioiodinated (R)-N-methyl-3-(2-iodophenoxy)-3- phenylpropanamine. Nucl Med Biol. 30:2003;697-706
39. Eckelman W.C. Sensitivity of new radiopharmaceuticals. Nucl Med Biol. 25:1998;169-173
40. Kung M.P., Stevenson D.A., Plossl K., Meegalla S.K., Beckwith A., Essman W.D., Mu M., Lucki I., Kung H.F. [99mTc]TRODAT-1 a novel technetium-99m complex as a dopamine transporter imaging agent. Eur J Nucl Med. 24:1997;372-380
41. 99mTc]TRODAT-1 as dopamine transporter imaging agents. J Med Chem. 41:1998;428-436